- Organizations: Neurotech Pharmaceuticals
Products
CMS assigns permanent J-code for Neurotech's ENCELTO cell therapy
The allogeneic encapsulated cell-based therapy is the first and only treatment approved by the FDA for the treatment of MacTel.
Business
BVI Medical and Neurotech name new CCOs
With over 20 years of executive leadership experience each, Andrew Chang and Beth Marsh will lead commercialization efforts for their respective companies’ upcoming product launches.
Products
FDA approves Neurotech's ENCELTO cell therapy for MacTel
Approval of revakinagene taroretcel-lwey is the first-ever for the treatment of this rare, neurodegenerative retinal disease.
Pipeline
FDA extends Neurotech's BLA PDUFA date for MacTel therapy
Review period of NT-501, an encapsulated cell therapy, now has a target date of March 2025.
Pipeline
Neurotech Pharma earns BLA priority review for MacTel cell therapy
Investigational ocular implant is designed to slow progression of gradual central vision deterioration in rare neurodegenerative retinal disease.
Products
Clinicians perform first FDA-approved ENCELTO treatment for MacTel
As the first-ever FDA-approved MacTel therapy, ENCELTO (revakinagene taroretcel-lwey) is a single-dose ocular implant administered via an outpatient vitreoretinal surgery.
Events